Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Terence Flynn has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising clinical data and competitive positioning in the market. The recent updates from ...

Intellia tried to allay some of those concerns on Saturday with new year-long data from the 36 patients treated in an early trial of its CRISPR drug for ATTR cardiomyopathy.

For reference, the recently approved CRISPR drug Casgevy costs $2.2 million for a course of treatment. Therefore, any ...

Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...